In This Article:
Lumos Diagnostics Holdings (ASX:LDX) Full Year 2024 Results
Key Financial Results
-
Revenue: US$11.1m (up 5.7% from FY 2023).
-
Net loss: US$8.59m (loss narrowed by 4.2% from FY 2023).
-
US$0.018 loss per share (improved from US$0.038 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lumos Diagnostics Holdings shares are up 19% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Lumos Diagnostics Holdings (at least 1 which is a bit concerning), and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.